The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,590.00
Bid: 12,590.00
Ask: 12,596.00
Change: 74.00 (0.59%)
Spread: 6.00 (0.048%)
Open: 12,566.00
High: 12,632.00
Low: 12,512.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Oil prices touch multi-month highs as OPEC+ expected to cap output

Mon, 04th Jan 2021 06:45

* Brent hits highest since March 2020; WTI at Feb 2020
levels

* OPEC+ set for meeting to discuss Feb production levels

* Most OPEC+ experts against Feb oil output rise - sources
(Updates prices, adds analysts' comments, adds latest on OPEC+,
adds remarks by Kuwait oil min, UK new vaccine rollout, changes
the dateline from Singapore)

By Bozorgmehr Sharafedin

LONDON, Jan 4 (Reuters) - Oil prices touched multi-month
highs on Monday on expectations OPEC and allied producers may
cap output at current levels in February and on hopes that
coronavirus vaccines may help curb the spread of the virus and
drive a strong economic rebound in the new year.

Prices rose in line with broader financial markets with
Brent crude futures reaching $53.33 a barrel, the
highest since March 2020. U.S. West Texas Intermediate (WTI)
crude touched $49.83 a barrel, the highest since February
2020.

March Brent crude futures were at $52.41 a barrel, up 61
cents, or 1.2%, by 0944 GMT and February WTI crude futures rose
35 cents, or 0.7%, to $48.87 a barrel.

"Price action today suggests that the market is assuming
that OPEC+ keeps the level of cuts unchanged for the upcoming
month," said ING commodities strategist Warren Patterson.

OPEC and allies, a group known as OPEC+, will meet on
Monday. Most OPEC+ experts voiced opposition to increasing oil
output from February when they met on Sunday, three OPEC+
sources told Reuters on Monday.

In December, OPEC+ decided to increase production by 0.5
million barrels per day (bpd) from January as part of a 2
million bpd gradual rise this year but some members have
questioned the need for a further boost due to spreading
coronavirus infections.

"The start of the new year is presenting challenges to the
OPEC+ group, as the balance of risks to oil demand recovery has
changed," BNP Paribas analyst Harry Tchilinguirian said.

"The OPEC+ producer group may have to re-schedule and delay
further tapering of voluntary supply cuts in view of latest
COVID developments," he added.

Mohammad Barkindo, secretary general of OPEC, said on Sunday
that the group saw plenty of downside demand risks in the first
half of 2021.

Kuwait's oil minister also said on Monday that he expected a
gradual recovery in oil demand, particularly in the second half
of 2021, as many countries around the world start to distribute
coronavirus vaccines.

Britain began vaccinating its population with the COVID-19
shot developed by Oxford University and AstraZeneca on
Monday.

Weaker dollar and strong manufacturing activities in Asia
also supported oil prices.

(Reporting by Bozorgmehr Sharafedin in London, additional
reporting by Florence Tan in Singapore; Editing by Bernadette
Baum)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.